Asset
Tipasertideg
Kymera Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04772885 | phase1 | completed | 2021-02-23 | 2022-10-20 | Kymera Therapeutics, Inc. | A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) |
FDA applications (0)
This company has no applications containing this asset.